Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetologia (2018) Vol. 61, Iss. 12, pp. 2461-2498
Open Access | Times Cited: 1344

Showing 26-50 of 1344 citing articles:

The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Juliana C.N. Chan, Lee‐Ling Lim, Nicholas J. Wareham, et al.
The Lancet (2020) Vol. 396, Iss. 10267, pp. 2019-2082
Closed Access | Times Cited: 291
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis
Tadashi Toyama, Brendon L. Neuen, Min Jun, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 5, pp. 1237-1250
Open Access | Times Cited: 271
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 642-653
Closed Access | Times Cited: 270
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 7, pp. 515-527
Open Access | Times Cited: 263
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. 839-848
Open Access | Times Cited: 234
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
Christopher J. Nolan, Marc Prentki
Diabetes and Vascular Disease Research (2019) Vol. 16, Iss. 2, pp. 118-127
Open Access | Times Cited: 231
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Management of diabetes and hyperglycaemia in the hospital
Francisco J. Pasquel, M. Cecilia Lansang, Ketan Dhatariya, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 3, pp. 174-188
Open Access | Times Cited: 226
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus
George Grunberger, Jennifer L. Sherr, Myriam Bermudez Allende, et al.
Endocrine Practice (2021) Vol. 27, Iss. 6, pp. 505-537
Closed Access | Times Cited: 203
Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes
Andrea Mario Bolla, Amelia Caretto, Andrea Laurenzi, et al.
Nutrients (2019) Vol. 11, Iss. 5, pp. 962-962
Open Access | Times Cited: 197
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
Raffaella Buzzetti, Jaakko Tuomilehto, Dı́dac Mauricio, et al.
Diabetes (2020) Vol. 69, Iss. 10, pp. 2037-2047
Open Access | Times Cited: 194
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 180
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Julio Rosenstock, Harpreet S. Bajaj, Andrej Janež, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 22, pp. 2107-2116
Open Access | Times Cited: 172
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
Kamlesh Khunti, Peter Knighton, Francesco Zaccardi, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 5, pp. 293-303
Open Access | Times Cited: 172
Metformin and COVID-19: From cellular mechanisms to reduced mortality
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 6, pp. 423-426
Open Access | Times Cited: 170
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 156
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 5, pp. 392-406
Closed Access | Times Cited: 148
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 145
Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials
Laura Chiavaroli, Danielle Lee, Amna Ahmed, et al.
BMJ (2021), pp. n1651-n1651
Open Access | Times Cited: 143
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
SV Madhu, Rajeev Chawla, B. M. Makkar, et al.
Indian Journal of Endocrinology and Metabolism (2020) Vol. 24, Iss. 1, pp. 1-1
Open Access | Times Cited: 141
Implicating the effect of ketogenic diet as a preventive measure to obesity and diabetes mellitus
Kumar Sachin, Tapan Behl, Monika Sachdeva, et al.
Life Sciences (2020) Vol. 264, pp. 118661-118661
Closed Access | Times Cited: 140
<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 161-174
Open Access | Times Cited: 139
Machine Learning Based Diabetes Classification and Prediction for Healthcare Applications
Umair Muneer Butt, Sukumar Letchmunan, Mubashir Ali, et al.
Journal of Healthcare Engineering (2021) Vol. 2021, pp. 1-17
Open Access | Times Cited: 125
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Kidney International Reports (2021) Vol. 7, Iss. 1, pp. 36-45
Open Access | Times Cited: 108
Diabetes and Stroke: What Are the Connections?
Ofri Mosenzon, Alice Cheng, Alejandro A. Rabinstein, et al.
Journal of Stroke (2023) Vol. 25, Iss. 1, pp. 26-38
Open Access | Times Cited: 105

Scroll to top